PBM Formulary Exclusions On The Rise, PhRMA Says
Access To Lower-Cost Insulin Affected
Executive Summary
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
You may also be interested in...
FTC Will Investigate Anti-Competitive Rebating
Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.
FTC Will Investigate Anti-Competitive Rebating But Any Enforcement Action Would Take Time
Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.